Suppr超能文献

多沙唑嗪可减轻糖尿病大鼠模型中由抗α-肾上腺素能受体抗体介导的肾基质重塑。

Doxazosin attenuates renal matrix remodeling mediated by anti-α-adrenergic receptor antibody in a rat model of diabetes mellitus.

作者信息

Zhao Lin-Shuang, Lin Yan-Yan, Liu Yi, Xu Chun-Yan, Liu Ye, Bai Wei-Wei, Tan Xue-Ying, Li De-Zhong, Xu Jin-Ling

机构信息

Department of Endocrinology, Wuhan General Hospital of Guangzhou Military Command, Wuhan, Hubei 430070, P.R. China.

Wuhan Clinical Medical School, Graduate College, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

出版信息

Exp Ther Med. 2017 Sep;14(3):2543-2553. doi: 10.3892/etm.2017.4827. Epub 2017 Jul 21.

Abstract

Diabetic nephropathy is a major complication of diabetes mellitus (DM). Recent studies suggest that immunological mechanisms have a key role in the pathogenesis of DM, therefore these mechanisms may be important targets for diabetes therapy. The present study evaluated the effects of anti-α-adrenergic receptor antibody (α-R Ab) mediation and doxazosin treatment in a rat model of DM. It was observed that levels of 24-h urinary protein, serum creatinine and transforming growth factor-β in DM were significantly increased after α-R Ab mediation (all P<0.05). In addition, electron microscopy identified severe damage in the renal tissue microstructures of DM rats following α-R Ab mediation, while only mild abnormalities were observed in that of healthy rats mediated with α-R Ab and of untreated DM rats. No marked abnormalities were observed in the renal tissue of healthy blank controls. Furthermore, in DM rats treated with α-R Ab mediation + doxazosin intervention, the expression of TGF-β significantly decreased, and renal functions and renal matrix remodeling were significantly improved, relative to untreated DM controls (P<0.01). These results suggest that α-R Ab may be involved in renal matrix remodeling during DM, and that kidney protection during DM may be achieved through treatment with corresponding receptor antagonists.

摘要

糖尿病肾病是糖尿病(DM)的主要并发症。最近的研究表明,免疫机制在糖尿病发病机制中起关键作用,因此这些机制可能是糖尿病治疗的重要靶点。本研究评估了抗α-肾上腺素能受体抗体(α-R Ab)介导和多沙唑嗪治疗对糖尿病大鼠模型的影响。观察到α-R Ab介导后,糖尿病大鼠的24小时尿蛋白、血清肌酐和转化生长因子-β水平显著升高(均P<0.05)。此外,电子显微镜检查发现α-R Ab介导后糖尿病大鼠肾组织微观结构有严重损伤,而用α-R Ab介导的健康大鼠和未治疗的糖尿病大鼠仅观察到轻度异常。健康空白对照组的肾组织未观察到明显异常。此外,与未治疗的糖尿病对照组相比,用α-R Ab介导+多沙唑嗪干预治疗的糖尿病大鼠中,TGF-β的表达显著降低,肾功能和肾基质重塑显著改善(P<0.01)。这些结果表明,α-R Ab可能参与糖尿病期间的肾基质重塑,并且通过用相应的受体拮抗剂治疗可以实现糖尿病期间的肾脏保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18c2/5609287/6655c6f9cb4e/etm-14-03-2543-g00.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验